Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,785,550
  • Shares Outstanding, K 123,348
  • Annual Sales, $ 48,660 K
  • Annual Income, $ -290,580 K
  • 60-Month Beta 1.71
  • Price/Sales 74.25
  • Price/Cash Flow N/A
  • Price/Book 4.07
Trade DNLI with:

Options Overview Details

View History
  • Implied Volatility 82.81% ( -0.50%)
  • Historical Volatility 78.00%
  • IV Percentile 81%
  • IV Rank 79.21%
  • IV High 92.24% on 09/23/22
  • IV Low 46.89% on 12/21/21
  • Put/Call Vol Ratio 0.11
  • Today's Volume 10
  • Volume Avg (30-Day) 71
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 1,792
  • Open Int (30-Day) 1,730

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.83
  • Number of Estimates 8
  • High Estimate -0.71
  • Low Estimate -0.91
  • Prior Year -0.69
  • Growth Rate Est. (year over year) -20.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.88 +18.59%
on 09/26/22
33.83 -9.29%
on 09/28/22
+2.89 (+10.40%)
since 08/30/22
3-Month
25.88 +18.59%
on 09/26/22
39.43 -22.17%
on 08/11/22
+1.26 (+4.28%)
since 06/30/22
52-Week
20.24 +51.63%
on 05/12/22
56.08 -45.27%
on 11/05/21
-19.76 (-39.17%)
since 09/30/21

Most Recent Stories

More News
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?

Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

DNLI : 30.69 (+4.78%)
ZYME : 6.15 (+5.85%)
Why Is Denali Therapeutics Inc. (DNLI) Down 27.4% Since Last Earnings Report?

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DNLI : 30.69 (+4.78%)
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping...

DNLI : 30.69 (+4.78%)
EVLO : 2.09 (+2.96%)
FHTX : 8.58 (+4.51%)
MRNA : 118.25 (+0.15%)
OMGA : 5.42 (+5.65%)
RUBY : 0.4338 (-6.71%)
SANA : 6.00 (+7.53%)
MCRB : 6.42 (+4.73%)
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus

Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.

SNY : 38.02 (+0.05%)
BIIB : 267.00 (+1.03%)
DNLI : 30.69 (+4.78%)
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

DNLI : 30.69 (+4.78%)
CDTX : 0.6280 (-3.40%)
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad...

DNLI : 30.69 (+4.78%)
Why Biotech Disruptor Ginkgo Bioworks Is Well-Positioned for the Future

Beaten down from its highs late last year, cell engineering company Ginkgo Bioworks now looks primed to divide and conquer.

DNA : 3.12 (-0.32%)
ZY : 2.78 (-0.71%)
BEAM : 47.64 (+0.29%)
DNLI : 30.69 (+4.78%)
Denali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Denali Therapeutics Inc. (DNLI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DNLI : 30.69 (+4.78%)
BPMC : 65.89 (+0.05%)
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions

Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in...

SPRC : 0.8393 (+8.94%)
DNLI : 30.69 (+4.78%)
SAGE : 39.16 (-1.11%)
SAVA : 41.82 (-2.90%)
ICPT : 13.95 (-14.99%)
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions

/PRNewswire/ -- In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the development of...

SPRC : 0.8393 (+8.94%)
DNLI : 30.69 (+4.78%)
SAGE : 39.16 (-1.11%)
SAVA : 41.82 (-2.90%)
ICPT : 13.95 (-14.99%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 36.06
2nd Resistance Point 34.42
1st Resistance Point 32.55
Last Price 30.69
1st Support Level 29.04
2nd Support Level 27.40
3rd Support Level 25.53

See More

52-Week High 56.08
Fibonacci 61.8% 42.39
Fibonacci 50% 38.16
Fibonacci 38.2% 33.93
Last Price 30.69
52-Week Low 20.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar